November 2023

(Bloomberg) — From small restaurants to high-tech corporations to a fuel plant run by Chevron Corp. , Israeli businesses are being rocked by the war against Hamas. SyriaInnovation and anti-obesity drug Lilly pushes for further weight loss in trial Saudi forces on alert after fatal clash with Houthi rebels Israel-Hamas escalation of war tests Qatar’s influence Sony’s Bungie gaming unit cuts back after title delayMa

Pathize Health has announced a new app to help people with chronic Covid monitor their energy levels throughout the day using biometrics.

Designed for Patients Immunocompromised by Severe COVID-19 ATLANTA, GA, October 30, 2023 (GLOBE NEWSWIRE) – via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company that is developing immunotherapies and vaccines for cancer and infectious diseases, today announced that it has begun planned site expansion for the Phase 2 clinical trial of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as the number one vaccine in immunocompromised patients.

In Los Angeles and elsewhere, some parents are struggling to find the new pediatric COVID vaccine, especially for children under 5. Not all pediatricians or pharmacies have it, even if vacunas. gov say so.

Reducing serotonin levels may be just the first step in losing light on the causes and possible remedies for long Covid.

For centuries, we’ve known that some viral infections peak in the winter months, but why is there seasonality associated with certain diseases?

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Nuvaxovid™ XBB. 1. 5 injectable dispersion of COVID-19 vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been approved for active immunization to save COVID-19 caused by SARS-CoV-2 in Americans aged 12 years and older in the European Union through the European Union’s Committee for Medicinal Products for Human Use (CHMP). Medicines Agency. European Communications

Novavax, Inc. (Nasdaq: NVAX), a global company developing protein-based vaccines with its Matrix-M™ adjuvant, announced that the European Commission has granted approval to the Nuvaxovid™ XBB. 1. 5 dispersion for COVID-19 injection. Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to save COVID-19 caused by SARS-CoV-2 in Americans 12 years and older. This resolution follows the positive opinion of the European Union Committee for Medicinal Products for Human Use.

Meanwhile, a quarter of the country’s wastewater sites are offline.